EGFR EXON 20 INSERTION MUTATIONS IN NSCLC
Each year, EGFR exon 20 insertion mutations could rob ~60,000 patients of time, hope, and life[1][2][3][4][5][6][7][8][9]
Time
Patients who have non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (EGFRm ex20ins NSCLC) have a 75% increased risk of death (HR=1.75) compared to patients who have common EGFR-tyrosine kinase inhibitor (EGFR-TKI) sensitive mutations* in their tumours (median OS 16.2 vs 25.5 months, respectively).[10] The precious time that patients have left is often tainted by the negative emotional burden of the disease.**[11]
Hope
Patients with EGFRm ex20ins NSCLC generally experience limited outcomes with currently approved EGFR-TKIs.[1][2] In fact, response rates of these patients to EGFR-TKIs are approximately one third of those observed in patients who have EGFRm NSCLC without an ex20ins mutation.†,[8]
Life
Due to the lack of effective targeted options, patients with EGFRm ex20ins NSCLC are most commonly prescribed chemotherapies as a first-line treatment, which are non-selective and have a wide range of side effects.[12][13][14][15]
Don’t miss the chance to treat EGFRm ex20ins NSCLC
Make EGFR exon 20 insertion mutations unmissable.
Discover more about EGFR exon 20 insertion mutations here:
What causes EGFR-TKI resistance?
Who do EGFR ex20ins mutations strike?
What impact do EGFR ex20ins mutations have on lives?
* EGFR exon 19 deletions and EGFR L858R point mutation.
** Qualitative interviews conducted with patients with NSCLC that had EGFR exon 20 mutations (n=10), 90% of whom had exon 20 insertion mutations. 100% of participants with EGFRm ex20ins NSCLC reported a psychological or emotional burden of their disease, and 60% described worries around treatment, the future, or finances.[11]
† Data taken from a meta-analysis of 61 studies, 12 of which reported overall response rate (ORR) in patients with EGFRm ex20ins NSCLC. Patient numbers not reported.[8] Mean ORR of patients with EGFRm NSCLC, without a detectable ex20ins mutation to EGFR-TKIs= 34.0% (13.9–84%). Mean ORR of patients with EGFRm ex20ins NSCLC to EGFR-TKIs= 11.9% (0.0–35.0%).[8]
EGFR, epidermal growth factor receptor; EGFRm, mutated EGFR; EGFR-TKI, EGFR-tyrosine kinase inhibitor; ex20ins, exon 20 insertion; HR, hazard ratio; mOS, median overall survival; NSCLC, non-small cell lung cancer; ORR, overall response rate.
CP-223640
